CDT
Conduit Pharmaceuticals Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$7.29M
P/E Ratio
—
EPS
$-1177.89
Beta
1.57
52W High
$1129.96
52W Low
$1.50
50-Day MA
$6.09
200-Day MA
$80.82
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on pioneering therapies for oncology and rare diseases, targeting substantial unmet medical needs in these critical areas. Utilizing its proprietary drug delivery technology, Conduit aims to enhance the effectiveness and safety of established treatments, thereby improving patient outcomes while reducing side effects. With a seasoned management team and a commitment to forming strategic alliances, the company is well-positioned to propel its innovative product pipeline forward and make a significant impact on the healthcare industry.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-24.74M |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -345.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-77.82 |
| Price-to-Book | 5.16 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -55.41 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $4.86M |
| Float | $2.29M |
| % Insiders | 77.87% |
| % Institutions | 0.00% |
More HEALTHCARE Stocks
Data last updated: 5/19/2026